Tuesday, 29 October 2013

MIM-D3 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on MIM-D3 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

Mimetogen Pharmaceutical’s MIM-D3 is under development for the treatment of DES and glaucoma. It is a small-molecule, peptidomimetic of nerve growth factor (NGF), a naturally-occurring protein in the eye that is responsible for the maintenance of the corneal nerves and epithelium, and the production of mucin and tears. While Restasis and many late-stage pipeline products address the inflammatory component of dry eye, MIM-D3 focuses on quickly and efficiently improving the quality of tears produced by the eye. By focusing on this underlying aspect of DES, MIM-D3 also addresses the symptoms of DES, including chronic dryness and grittiness of the ocular surface. Both NGF and brain-derived growth factors have been determined to influence mucin secretion from the conjunctiva, including MUC 5AC. MIM-D3 is a tyrosine kinase receptor agonist that stimulates MUC 5AC secretion from the conjunctival goblet cells.

Scope

- Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MIM-D3 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MIM-D3 for the top two countries from 2012 to 2022.
- Sales information covered for Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for DES
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of MIM-D3 performance
- Obtain sales forecast for MIM-D3 from 2012-2022 in top two countries (Japan and China)

To view the table of contents and know more details please visit MIM-D3 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022 report. 

Similar Reports:

2013 Deep Research Report on Global and China Solar Grade Polysilicon Industry

Reportstack has announced a new market research publication on 2013 Deep Research Report on Global and China Solar Grade Polysilicon Industry which was professional and depth research report on global and China solar grade polysilicon industry.  This report firstly introduces polysilicon definition classification industry chain etc relation information. Then introduced polysilicon manufacturing technology and process (Siemens or FBR).At the same time, introduced key processes specifications and applications. And then SumAugy statistics of Global and China major polysilicon manufacturers 2009-2016 solar grade (SG) and Electronic grade (EG) polysilicon capacity production supply demand (mainly according silicon crystalline solar cell demand and semiconductor wafer demand) shortage and polysilicon selling price cost profit Margin and production value. And also introduced international 28 and China 40 major polysilicon companies basic information, EG EG polysilicon capacity production price cost profit Margin and production value etc details information and polysilicon project Siemens CVD reactor sources or Project design and construction services partners. and also introduced polysilicon materials cost, electricity cost, Depreciation cost,Labor cost etc polysilicon manufacturing cost and cost structure (especially Cold hydrogenation for low cost polysilicon), all data include 2009-2012 history data and 2013-2016 forecast data. Finally, this report introduced 3000ton/year polysilicon project feasibility analysis and investment return analysis.also give related research conclusions and development trend analysis of China polysilicon industry. In a word, it was a depth research report on Global and China polysilicon industry.
To view the table of contents and know more details please visit 2013 Deep Research Report on Global and China Solar Grade Polysilicon Industry.

Global and China General Aviation Industry Report, 2013-2015

Reportstack has announced a new market research publication on Global and China General Aviation Industry Report, 2013-2015. Recent years have seen thriving Chinese economic development which has brought with huge demand for the aviation business. As a result, business aviation, private aviation, emergency, industrial aviation and agricultural and forestry aviation are expected to embrace for substantial growth potential. The implementation of new measures for the administration of general aviation, coupled with loosened access to the general aviation market drives the general aviation an investment appeal. In 2001, China general aviation industry geared up for development, with the business volume by 2012 breaking 500,000 hours.

China general aviation industry lags far behind the developed countries, albeit vigorous growth in recent years. Take America for example, when its GDP hit USD1 trillion, its helicopters for civil use amounted to more than 8,000 ones, as opposed to China’s 80 when it developed at the same level.

By 2020, China’s demand for utility aircrafts will hit 10,000 ones, of which, 6,000 will be piston-powered ones, 2,000 turboprop-powered, 500 business jet aircrafts, 1,000 helicopters, and 500 others, with the targeted market size claiming RMB150 billion; provided the industrial driving ratio of 1:10, the output scale of the entire general aviation industry is expected to reach RMB1.5 trillion, according to the estimation from CAST,  Chinese Society of Aeronautics and Astronautics, and China General Aviation Association.

The report predicts the development trend of global and China general aviation industry, and highlights the operation of key enterprises at home and abroad as well as their development planning.

CITIC Offshore Helicopter (000099) is mainly engaged in maritime helicopter transport, onshore general aviation and general aviation maintenance businesses, as the largest maritime helicopter transport service provider and the largest general airline company in China which occupies nearly 60% market share of China’s maritime helicopter transport business.

In 2013H1, the revenue of CITIC Offshore Helicopter rose by 2.79% year-on-year to RMB521 million, with the net income jumping by 19.1% year-on-year to RMB82.07 million, with the air time of general aviation hitting 13,691 hours and 23 minutes and 17, 150 flight movements, respectively, up 9.87% year-on-year and 18.5% year-on-year.
To view the table of contents and know more details please visit Global and China General Aviation Industry Report, 2013-2015.

China Sportswear Industry Report, 2013-2016

Reportstack has announced a new market research publication on China Sportswear Industry Report, 2013-2016. The sportswear mainly consists of sports footwear, sports apparel and accessories. USA, China, Japan and Brazil are the four largest sportswear markets around the globe, with revenue sharing more than half of globe’s total.

Since 2012, in addition to the increasingly challenging macro-economic and retail environment in China, the sportswear industry continued to be overcrowded with intensified competition and high inventory, and the focus for retailers is still on clearing inventory and improving profitability.

Under the background, the enterprises have to reduce the inventories and relieve the dilemma through shutting up shops, industrial promotion and channel transformation. According to incomplete statistics, in H1 2013, Lining, Anta, Peak, China Dongxiang and Xtep totally closed over 2000 stores.

In H1 2013, the revenue and net income of 6 local major listed sports brands all witnessed negative growth. Anta features the highest revenue (RMB3366.5 million) and the smallest year-on-year decline rate (14.43%). China Dongxiang characterizes the lowest revenue (RMB563.0 million) and biggest decline rate (32.30%).

Lining behaves the worst. During 2012-H1 2013, Lining was in a loss state. In H1 2013, the company suffered loss of RMB184.2 million.

Since capacity expansion was faster than demand growth, China’s traditional sportswear market entered a structural adjustment period in 2012. It is predicted that the sportswear industry in China will still encounter the oversupply, shrinking demand and challenges on offline channels from online channels in future several years, and the integration of whole industry will last at least 2-3 years.

China Sportswear Industry Report, 2013-2016 mainly consists of the followings:

- Development of sportswear industry in China: changes of enterprises’ profitability and number of stores;
- Revenue of sportswear industry in China, and revenue, marketing channels, etc. of three segment markets (Footwear, Apparel and Accessories);
- Competition pattern of sportswear market in China: brand awareness, market competition pattern and regional competition;
- Analysis on 3 major international sportswear enterprises as Nike, Adidas and Puma, including operation, revenue structure, gross margin, number of stores and development in China;
- Analysis on 9 major sportswear brand enterprises in China (Lining, Anta, 361 Degrees, Xtep, Peak, China Dongxiang, Hongxing Erke, Qiaodan Sports and GRN), including operation, revenue structure, gross margin, number of stores, sales mode, development strategy and performance prediction in future 3 years. 
To view the table of contents and know more details please visit China Sportswear Industry Report, 2013-2016.

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019

Reportstack has announced a new market report on Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. The analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period.

Scope
- Disease overview along with treatment algorithms and treatment usage patterns
- Market size and forecast for the macular degeneration market in APAC from 2012 to 2019
- Major marketed products in the APAC along with a heat map
- In-depth analysis of pipeline along with clinical trial failure analysis
- Key drivers and restraints that have had a significant impact on the market
- Key licensing and co-development agreements in the macular degeneration market

Reasons to Buy
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

To view the table of contents and know more details please visit Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 report

Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Arimenda is a once-daily fixed-dose combination (FDC) of an ER form of memantine, an NMDA receptor antagonist, and donepezil, an AChEI. It is developed to overcome low compliance in patients who are taking the two drugs separately. It provides full-strength dosing from the start of treatment to enable a more rapid and convenient attainment of therapeutic plasma levels of the two compounds.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Arimenda including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Arimenda for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Arimenda performance
- Obtain sales forecast for Arimenda from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

To view the table of contents and know more details please visit Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 report. 

Similar Reports:


Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Lu AE58054 is a selective serotonin 5-HT6 receptor antagonist under development by H. Lundbeck and its partner Otsuka Pharmaceutical. 5-HT6 receptors have become an attractive target in research on cognitive disorders after the discovery that instead of acting on the dopaminergic system, 5-HT6 activation enhances cholinergic excitatory neurotransmission (Upton et al., 2008).

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lu AE58054 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lu AE58054 for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lu AE58054 performance
- Obtain sales forecast for Lu AE58054 from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

To view the table of contents and know more details please visit Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 report. 

Similar Reports: